Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223631 | 1.00 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL5575317 | 1.00 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL3192032 | 1.00 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL6206953 | 1.00 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL17816948 | 0.85 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL15143001 | 0.85 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL4124556 | 0.85 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL6479731 | 0.85 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL7158782 | 0.83 | POLB (0.58) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL6714428 | 0.83 | POLB (0.58) | POLBGAAALOX12KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8968711-B2 | Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process | L'OREAL (FR) | 2015-03-03 | — | — | US | claimed |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | L'OREAL (FR) | 2010-10-28 | — | — | US | claimed |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | L'OREAL (FR) | 2010-09-23 | — | — | US | claimed |
| JP-2007528404-A | — | — | 2007-10-11 | — | — | JP | claimed |
| EP-1319007-B9 | FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2007-10-10 | — | — | EP | claimed |
| EP-1734942-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | claimed |
| EP-1319007-B1 | FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2006-03-01 | — | — | EP | claimed |
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | claimed |
| WO-2005087215-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| EP-1319007-A1 | FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2003-06-18 | — | — | EP | claimed |
| EP-0863872-B1 | PREPARATION OF CHIRAL 3-HYDROXY-2-PYRROLIDINONE DERIVATIVES | SYNGENTA LTD (GB) | 2002-05-29 | — | — | EP | claimed |
| WO-2002024702-A1 | FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| EP-0863872-A1 | PREPARATION OF CHIRAL 3-HYDROXY-2-PYRROLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1998-09-16 | — | — | EP | claimed |
| US-5710283-A | Preparation of chiral pyrrolidinone derivatives | ZENECA LIMITED (GB) | 1998-01-20 | — | — | US | claimed |
| WO-1997019920-A1 | PREPARATION OF CHIRAL 3-HYDROXY-2-PYRROLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1997-06-05 | — | — | WO | claimed |
| EP-4238966-B1 | TETRAHYDRONAPHTHALENE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-12497378-B2 | Tetrahydronaphthalene compounds, pharmaceutical compositions, and uses thereof | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| EP-0114172-A1 | Anti-inflammatory composition | MERCK & CO. INC. (US) | 1984-08-01 | — | — | EP | disclosed |
| US-4389525-A | Process for the resolution of some interphenylene 9-thia-11-oxo-12-azaprostanoic acids | MERCK & CO., INC. (US) | 1983-06-21 | — | — | US | disclosed |
| US-4379792-A | Anti-inflammatory composition | MERCK & CO., INC. (US) | 1983-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | DNPEP, ASPH, PEPD | POLB 1917/4885GAA 192/4885ALOX12 2756/4885 |
| US-12497378-B2 | Tetrahydronaphthalene compounds, pharmaceutical compositions, and uses thereof | CYP11B2, HTT, REN | POLB 3817/4885GAA 1714/4885ALOX12 1244/4885 |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | CUTA, SUCLG1, KRT18 | POLB 1148/4885GAA 342/4885ALOX12 894/4885 |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | ACMSD, CUTA, PCCA | POLB 705/4885GAA 654/4885ALOX12 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.